fenofibrate can suppress B cell lymphoma

What is it about?

Obesity is associated with an increased risk for malignant lymphoma development. The PPAR alpha agonist fenofibrate was tested for its lipid metabolism modulation properties. Fenofibrate stimulated FFA uptake by the liver and restored hepatic FA oxidation capacity, accelerating the clearance of lipids released from WAT and blocked hepatic lipid release induced by the tumors.

Featured Image

Why is it important?

Our data show that fenofibrate associated effects on hepatic lipid metabolism and deprivation of serum lipids are capable to suppress B-cell lymphoma growth which may direct novel treatment strategies